Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy

Related Experiment Videos

Jae J Chae1, Ivona Aksentijevich, Daniel L Kastner

  • 1Laboratory of Clinical Investigation, National Institutes of Arthritis and Musculoskeletal and Skin Diseases, Genetics and Genomics Branch, Bethesda, MD 20892-1849, USA. chaej@exchange.nih.gov

Insights

Familial Mediterranean fever (FMF) is an autoinflammatory disease caused by MEFV gene mutations. Understanding pyrin

Area of Science:

  • Immunology
  • Genetics
  • Molecular Biology

Background:

  • Familial Mediterranean fever (FMF) is a systemic autoinflammatory disorder with recurrent fever and inflammation.
  • FMF is caused by recessively inherited mutations in the MEFV gene, encoding pyrin.
  • High carrier frequencies of MEFV mutations exist in Eastern Mediterranean populations.

Purpose of the Study:

  • To elucidate the molecular pathogenesis of FMF.
  • To identify pyrin's regulatory role in inflammation.
  • To explore new therapeutic targets for FMF.

Main Methods:

  • Analysis of pyrin's interactions with apoptosis-associated speck-like protein (ASC) and caspase-1.
  • Investigating pyrin cleavage by caspase-1.
  • Examining the nuclear translocation and NF-kappaB activation effects of cleaved pyrin.

Main Results:

  • Pyrin regulates caspase-1 activation and IL-1beta production via its PYRIN and B30.2 domains.
  • Caspase-1 cleaves pyrin, leading to nuclear translocation of its N-terminal fragment.
  • Cleaved pyrin enhances ASC-independent NF-kappaB activation.

Conclusions:

  • Pyrin's cleavage by caspase-1 is crucial for FMF pathogenesis.
  • Understanding pyrin's function offers insights into autoinflammatory mechanisms.
  • Pyrin cleavage presents a potential therapeutic target for FMF.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...